Previous studies have shown that the BCL-2 protooncogene encodes a mitochondrial protein that promotes cell survival by blocking programmed cell death. &l-2 protein has been detected in normal immature myeloid cells and in acute myeloid leukemia (AML) cells. To assess its functional role in normal and leukemic hematopoiesis, we performed serumfree cultures of CD34+ normal marrow cells, of bcl-2-positive myeloid lines. and of AML cells in the presence of bcl-2 sense, nonsense, and antisense phosphorothioate oligodeoxynucleotides. In all antisense-treated cultures, we ob-HE BCL-2 PROTOONCOGENE was initially described because of its involvement in the t( 14; 18) translocation present in most follicular lymphomas, where it is juxtaposed to the JH region of the Ig heavy chain gene.'** This rearrangement results in the production of high levels of normal bcl-2 transcripts, which seems to be a major factor of transformati~n.~.~ Despite the lack of t( 14; 18) translocation, high levels of BCL-2 RNAs or bcl-2 protein have also been detected in other lymphoid malignancies such as nonfollicular lymphomas, chronic lymphocytic leukemia, and plasma cell dyscra~ias.~.~ The BCL-2 gene encodes a 26-M) protein that promotes cell survival by blocking programmed cell death (also termed apoptosis).6 BCL-2-transfected cell lines exhibit prolonged survival in growth-factor deprived medium and greater resistance to stresses such as heat-sh~ck.'.~ Recently, it has been shown that BCL-2 gene overexpression in murine lymphoid lines or in a human leukemia line conferred a high resistance to a variety of chemotherapeutic agents by blocking druginduced apopto~is.'*'~ Immunohistochemical analyses have shown that bcl-2 protein is normally expressed in the mantle zone of lymph nodes and in medullary thymocytes, and also in T and B blood lymphocyte^.^.' However, bcl-2 expression is not restricted to the lymphoid lineage; nonlymphoid tissues characterized by apoptotic cell turnover such as skin, intestinal epithelium, and bone marrow were found to be bcl-2-positive by immunohistologic techniques." Delia et a l l z showed by flow cytometry and Western blot analysis that bcl-2 is expressed in immature normal myeloid cells and in myeloid cell lines such as KG1, HL-60, and K562. Moreover, in a study of 75 marrow or blood samples from patients with newly diagnosed acute myeloid leukemia (AML), we observed that bcl-2 protein could be detected by flow cytometry in most cases.I3 Highest levels were associated with prolonged cell survival in growth factor-deprived liquid culture, and with poor patient outcome after cytostatic treatment by failure to achieve complete remission. Taken together, these facts suggest that bcl-2 plays an important role in the survival of hematopoietic cells from the proliferating compartment, and that it can be implicated in the resistance of leukemic cells to chemotherapy.
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Antisense oligonucleotides specific for BCL-2 RNA sequences have already been used to modify the growth and survival in culture of a bcl-2-positive lymphoid cell line.14 We report here on the effect of BCL-2 antisense oligomers on the expression of bcl-2 protein and on the in vitro survival of normal and leukemic myeloid cells.
MATERIALS AND METHODS

Cells.
Three human leukemiallymphoma cell lines were studied: Daudi, a Burkitt's lymphoma derived line used as bcl-2-negative controli5; and KGla (myeloblastic) and HL-60 (promyelocytic), which are both b~l-2-positive.'~~'~ Experiments with fresh AML cells were conducted on three samples obtained from consenting patients at diagnosis. The first two samples were selected because of their high percentages of bcl-2-positive cells (AML no. 1 and AML no. 2), and the thud one (AML no. 3) served as negative control. According to French-AmericanBritish (FAB) recommendations.i6 diagnoses were M1 (AML no. l), M5 (AML no. 2), and M2 (AML no. 3). Leukemic cells were collected by bone marrow aspiration into heparinized syringes, separated by Ficoll density gradient, washed, and resuspended in RPMI-1640. Cytocentrifuge slides showed that all samples contained more than 95% blasts cells.
Normal marrow was obtained from allogeneic bone marrow transplant donors. CD34' cells were prepared by the AIS MicroCELLector system (Applied Immune Sciences, Menlo Park, CA) according to the instructions of the manufacturer. Briefly, Ficoll-separated cells were incubated for 1 hour in a Soybean Cell Culture Flask (Applied Immune Sciences) at room temperature. Supernatant cells were then incubated for 1 hour in a CD34 culture flask selection. CD34+ cells were detached, washed, and resuspended in WMI-1640. The percentage of CD34+ cells in the suspension was higher than 90% in all experiments.
Preparation of oligodeoxynucleotides. Sense and antisense 20- mer phosphorothioate oligodeoxynucleotides directed to the translation initiation site of BCL-2 transcripts were purchased from Geneset SA (Paris, France). Preparation was performed as described by Reed et all4 according to the following sequences: S'-GGGAAGGAT-GGCGCACGCTG-3' (sense) and 5'-CAGCGTGCGCCATCC-'ITCCC-3' (antisense). In preliminary experiments performed with HL-60 cells, nonsense oligonucleotides with the same base composition (5'-TCGCCACTCGATCCTGCCCG-3') were used as well. Oligonucleotides were suspended in Hank's Buffered Salt Medium after control of purity and stored at -20°C. 
Cell cultures.
Cells were cultured in serum-free conditions in 96-well flat-bottomed microtiter plates (Falcon; Becton Dickinson Labware, Lincoln Park, NJ). A total of S X IO4 viable cells (leukemic lines) or 1.5 X 105 cells (AML and CD34+ cells) were placed into wells containing 200 p L of RPMI-1640 medium supplemented with 2 mmol/L glutamine, 50 U/mL of penicillin, 0.1 mglmL of streptomycin, and 15% QSBF-5 1 concentrated supplement (TechGen International, Les Ullis, France). Cells were then incubated at 37°C in a fully humidified atmosphere with 5% CO2 for the appropriate time (8 to 15 days). On day 0, 50 pmol/L of oligodeoxynucleotides was added in cultures. On day 6. 5 prnolk of the same oligomer was added.
In some experiments, daunorubicin (DNR) or l-P-D-arabinofuranosyl-cytosine (Ara-C) were added on day 0 at respective concentrations of 0.05 to S pg/mL and 0.4 to 20 pg/rnL, respectively.
All experiments were performed in duplicate or triplicate (according to the number of cells available).
Cell viability and progetzitor ussuys. At intervals depending on the experiment, cells were resuspended and removed from each well for the analysis of number and viability, clonogenic properties, and antigen expression. Cell counts were performed on days 2, 4, 6, 8, 1 I , and 15 in the presence of trypan blue dye to determine the concentration of viable cells.
Normal (colony-forming unit granulocyte-macrophage [CFU-GM] and CFU-granulocyte, erythroid, monocyte, megakaryocyte [CFU-GEMM]) and leukemic (Cm-leukemia [CFU-L]) progenitor assays were performed on days 0, 4 (when cultures were treated with cytotoxic drugs), 6, and I 1 as follows. Cells were washed three times with RPM1 medium, resuspended at a concentration of 2.5 X IO4 viable cellslmL in 200 p L Iscove's modified Dubelcco's medium supplemented with 0.8% methylcellulose (Sigma Chemical CO, St Louis, MO) and 30% fetal calf serum (GIBCO, Paisley, UK). 5637 bladder carcinoma cell line supernatant (HTB9) at a final concentration of 12% and (for CFU-GEMM assay) 2 UlmL of erythropoietin (Terry Fox Laboratories, Vancouver, Canada) were added as growth factors. Cells were plated onto 96-well flat-bottomed plates. Colonies (more than 50 cells) were counted on days 7 ( C m -L ) and 14 (CFU-GM and CFU-GEMM).
Immunojuoreucence ussrcys. Bcl-2 staining was described in details elsewhere.'' Briefly, cells were washed, permeabilized for 30 minutes in phosphate-buffered saline (PBS) with 70% ethanol, washed twice, and resuspended in PBS with 1% human AB serum. Cells were then incubated for 30 minutes at 4°C with anti-bcl-2 monoclonal antibody (MoAb; Dakopatts, Glostrup, Denmark). After two washings in PBS, fluorescein-conjugated goat antimouse minutes at 4°C with a fluorescein-conjugated CD15 MoAb (Dakopatts), washed twice, and then incubated with the bcl-2 MoAb (Dakopatts) after permeabilization in 0.25% paraformaldehyde (for 15 minutes at room temperature) and 70% methanol (for 1 hour at 4°C). Phycoerythrin-conjugated antimouse F(ab')z fragments were used as second layer.
RESULTS
Oligonucleotide concentration. These experiments were performed with HL-60 cells. As shown in Fig 1, antisense oligonucleotide decreased the number of viable cells in a concentration-dependant manner. The maximal effect was observed at day 11 (30% cell survival at a concentration of 50 pmol/L). Sense or nonsense oligonucleotides had a limited but significant toxic effect on day 11. The addition of 10% of the initial dose on day 6 resulted in a more efficient inhibition with no remaining cell on day 11 at an initial dose of 50 pmoVL. This addition did not significantly increase sense or nonsense oligonucleotide toxicity. Therefore, an initial dose of 50 pmoVL with an additional dose of 5 pmol/ L on day 6 was used throughout the study.
Bcl-2 and surjace marker expression. The initial percentages of bcl-2-positive cells were 75% for CD34' cells, 98% for KGla cells, 92% for HL-60 cells, and 3% for Daudi cells (negative control). In the three leukemia samples studied, these percentages were, respectively, 89%, 78%, and 8%. These values decreased moderately throughout the culture in controls. Treatment by sense or nonsense oligomers For personal use only. on November 11, 2017. by guest www.bloodjournal.org From aao CDI1* CLLLO did not modify the expression of bcl-2 when compared with controls. By contrast, the percentage of bcl-2-positive cells decreased dramatically by day 6 and we observed an almost complete disappearance of bcl-2-positive cells by day 11. Detailed results are presented in Table 1. A quantification of mean fluorescence intensity in bcl-2-positive cell lines showed a decrease correlated to that of the percentage of bcl-2-positive cells. The calculated MESF values for HL-60 and KGla are indicated in Table 2 . An example of flow cytometry analysis is presented in Fig 2. The evolution of CD34 expression was studied in a KGla line, in CD34-sorted cells, and in the two CD34+ AML samples (AML no. 1 and AML no. 2). Initially, the respective percentages of CD34' cells were 97%, 96%, 60%, and 78%. At day 11, these percentages remained similar (89%, SO%, 48%, and 68%, respectively) in sense-treated cultures, but were significantly decreased (29%, 25%, 37%, and 26%) in antisense-treated samples. CD15 expression was not modified by culture conditions. A representative diagram of CD15 versus bcl-2 staining of HL-60 cells before and after antisense treatment is provided in Fig 3. Cell survival in liquid culture. Cells were cultured for 15 days or until death with or without sense or antisense oligodeoxynucleotides. Sense oligonucleotides had little effect on cell survival when compared with controls. However, the number of cells remaining at day 15 was 10% to 25% lower (median, 16%) in the sense-treated cultures than in controls. By contrast the number of viable cells in antisensetreated cultures was significantly decreased in cell samples that were initially bcl-2-positive (CD34' cells, KGla and HL60 lines, and 2 AML samples). The effect of antisense treatment was really noticeable at day 6 or 8, and no viable cells remained by day 15 except for CD34' cells (22% of initial number). The bcl-2-negative line (Daudi) and AML sample (AML no. 3) were not affected by antisense treatment. Detailed results are presented in Fig 4 and 5. The survival of clonogenic cells in liquid culture is presented in Table 3 . At day 6 of liquid culture, the number of KGla colonies and CFU-L from bcl-2-positive AML cases decreased in the presence of antisense oligomers, whereas it remained stable until day 11 in the cultures treated with sense oligomers. The number of CFU-L in the bcl-2-negative leukemia was initially high but rapidly decreased in the sense-as well as in the antisense-treated cultures.
Sensitivity to cytostatic drugs. AML cells were treated with two cytostatic drugs, DNR and Ara-C. The optimal concentration of each drug for this study was determined to decrease the number of day-8 cells in culture by approximately 50% (data not presented). These concentrations were 0.5 lg/mL for DNR and 4 pg/rnL for Ara-C. Figure 5 shows that the cytotoxic effect of both drugs was more effective in antisense-treated cultures.
The sensitivity of CFU-L to chemotherapy was also highly increased in antisense-treated cultures, as shown in Table 4 .
DISCUSSION
The BCL-2 gene encodes a membrane protein located in the inner mitochondrial membrane6 and probably in endoplasmic reticulum and perinuclear membrane. initially discovered in the lymphoid lineage, Bcl-2 protein can be detected in hematopoietic cells and myeloid leukemia cells. In this study, we investigated its functional role by blocking its expression. The possibility of using antisense oligomers as inhibitors of oncogenes implicated in cell proliferation such as c-myc and c-myb has already been documented in hematopoietic cell lines and in chronic myeloid leukemia cell~.'~.'' We used here phosphorothioate oligodeoxynucleotides according to the results obtained by Reed et all4 in a bcl-2-transfected lymphoid line. Our data show that the effects of antisense oligomers could be observed at days 4 to 6, and that bcl-2 protein was no longer detectable by day 1 1. The delay in protein-expression decrease may be explained by the use of phosphorothioate rather than normal phosphodiester oligomers, because phosphorothioate oligomers attain their highest intracellular concentration after 4 or 5 days.22 This delay may also be explained by a long protein half-life, as can be observed in resting lymphocytes in which bcl-2 protein can be detected in the absence of RNA.23
The decrease of bcl-2 protein content in antisense-treated cultures was followed by rapid cell death, whereas sensetreated cells survived for more than 15 days despite of the absence of growth factors. A limited toxicity of sense oligomers was observed, as already reported when phosphorothioate oligonucleotides are used.I4 The effect on cell survival was observed for all cell types studied, except for the Daudi line and for the bcl-2-negative leukemia sample. In this last case, cell survival was short regardless of oligonucleotide treatment and similar to that of antisense-treated bcl-2-positive leukemia cells. On the contrary, Daudi cells could be maintained in the same culture conditions until day 15, which indicates that other survival mechanisms were implicated or that this line was not involved in programmed cell death. The mechanism by which bcl-2 protein interferes with programmed cell death is not known. It has been recently demonstrated that it is implicated in oxydative metabol i s m~. *~ Immunolocalization studies have shown that bcl-2 is expressed in nonlymphoid cells with long-term survival such as neurons" and in tissues characterized by complex proliferation and differentiation processes such as skin and bone marrow. Our experiments show that the decrease of bcl-2 expression in cultured cells was associated with a decreased number of clonogenic cells and with cell maturation, as indicated by the loss of stem-cell marker CD34. This finding might argue that bcl-2 is necessary to maintain hernatopoietic cells of the proliferating compartment possibly to facilitate the action of other mechanisms directly implicated in cell proliferation. Indeed, experiments with doubly transgenic mice have suggested that bcl-2 could cooperate with other oncogenes controlling proliferation such as cmyc.25.26 However, our data are in contradiction with the report by Veis et alZ7 that bcl-2-deficient mice exhibit normal red blood cells and neutrophil counts and normal marrow cellularity, whereas lymphoid tissues are subject to rapid apoptosis after birth. It is likely that in vivo conditions can provide other mechanisms of hematopoietic cell survival. It is also possible that human hematopoiesis is more dependent on BCL-2 expression, or that the role of BCL-2 is more important in adult tissues.
Many drugs commonly used in the treatment of AML have been reported to induce DNA fragmentation and apoptotic cell death.28329 Overexpression of BCL-2 gene in murine or human cell lines confers a high level of resistance to a variety of chemotherapeutic agents.'"' Moreover, the clinical course of patients with lymphomas" or acute l e~k e m i a '~.~' seems to be worse when malignant cells express high levels of bcl-2. In this study, we examined the effects of two major antileukemic drugs on fresh leukemia cells. The inhibition of bcl-2 expression resulted in increased susceptibility of the two bcl-2-positive AML samples. Although the mechanism by which bcl-2 protects cells from chemotherapy damage is not known, our results confirm its implication in drug resistance of AML cells. 
